Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalidixic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalidixic Acid SCHEMBL29367723 | 1.00 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL7878858 | 1.00 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL4766415 | 0.99 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL950987 | 0.99 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL9743582 | 0.99 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL27256972 | 0.99 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL11472599 | 0.95 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL11479648 | 0.95 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL28206277 | 0.95 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL2322952 | 0.94 | KMT2A (0.88) | KMT2AMEN1LMNAABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32835 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116772670-B | Method, system and equipment for determining safe distance of tunnel blasting excavation air shock wave | PowerChina Huadong Engineering Corp.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4743098-A1 | THERAPEUTIC USE OF FIBROBLASTS FOR THE TREATMENT OF PSORIASIS | FibroBiologics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-121622671-B | Application of meropenem or aztreonam combined with nalidixic acid in preparation of antibacterial drugs | 山东省妇幼保健院 | 2026-05-15 | — | — | CN | claimed |
| CN-122012447-A | Application of phosphoenolpyruvate synthase T419D mutation site | 云南大学 | 2026-05-12 | — | — | CN | claimed |
| WO-2026090082-A2 | METHODS FOR PREVENTION OF INSTANT BLOOD-MEDIATED INFLAMMATORY REACTION IN CELL BASED THERAPEUTICS | FIBROBIOLOGICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4716749-A2 | METHODS OF PRODUCING LARGE-SCALE PLASMID LIBRARIES | The General Hospital Corporation (US) | 2026-04-01 | — | — | EP | claimed |
| US-4293539-A | Controlled release formulations and method of treatment | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| US-4288543-A | SAMPLING IN LIQUID PHASE WITH ANTIGROWTH AGENTS-BIOLOGICAL | PFIZER INC. (US) | 1981-09-08 | — | — | US | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
| US-4264730-A | Medium for determining sensitivity of Klebsiella and Enterobacter organisms to selected antibiotics | MCDONNELL DOUGLAS CORPORATION (US) | 1981-04-28 | — | — | US | claimed |
| EP-0025698-A2 | Controlled release formulations | ELI LILLY AND COMPANY (US) | 1981-03-25 | — | — | EP | claimed |
| US-4207418-A | BACTERICIDE | STERLING DRUG INC. (US) | 1980-06-10 | — | — | US | claimed |
| US-4190495-A | GROWING MICROORGANISM CONTAINING RECOMBINATE DNA-CONTAINING CLONING VECTOR FOR REPLICATION OF VECTOR | RESEARCH CORPORATION (US) | 1980-02-26 | — | — | US | claimed |
| US-4038409-A | FUNGICIDES, BACTERICIDES, PROTOZOICIDES | SYNTEX (U.S.A.) INC. (US) | 1977-07-26 | — | — | US | claimed |
| US-3960757-A | HYDROPHOBIC | TOYO JOZO CO., LTD. (JA) | 1976-06-01 | — | — | US | claimed |